PT - JOURNAL ARTICLE AU - Capai Lisandru AU - Ayhan Nazli AU - Masse Shirley AU - Canarelli Jean AU - Priet Stéphane AU - Simeoni Marie Helene AU - Charrel Remi AU - de Lamballerie Xavier AU - Falchi Alessandra TI - Seroprevalence of SARS-CoV-2 IgG antibodies, in Corsica (France), April and June 2020 AID - 10.1101/2020.09.29.20201368 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.29.20201368 4099 - http://medrxiv.org/content/early/2020/09/30/2020.09.29.20201368.short 4100 - http://medrxiv.org/content/early/2020/09/30/2020.09.29.20201368.full AB - Our aim was to assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection after the lockdown in a sample of the Corsican population. Between 16th April and 15th June 2020, 2,312 residual sera were collected from patients having carried out a blood analysis in one of the participating laboratories. Residual sera obtained from persons of all ages were tested for the presence of anti-SARS-CoV-2 IgG using the EUROIMMUN enzyme immunoassay kit for semiquantitative detection of IgG antibodies against S1 domain of viral spike protein (ELISA-S). Borderline and positive samples in ELISA-S were also tested with an in-house virus neutralization test (VNT). Prevalence values were adjusted for sex and age. A total of 1,973 residual sera samples were included in the study. The overall seroprevalence based on ELISA-S was 5.27% [95% confidence interval (CI) 4.33-6.35] and 5.46% [4.51-6.57] after adjustment. Gender was not associated with IgG detection. However, significant differences were observed between age groups (p-value = 1 E-5) and particularly for people being younger than 50 years of age (Odd ratio (OR) = 2.86 95% CI [1.80-4.53]; p-value <0.000001*). The prevalence of neutralizing antibody titers ≥40 was of 3% [2.28-3.84]. In conclusion the present study showed that a low seroprevalence for COVID-19 in Corsica in accordance with values reported for other French regions in which the impact of the pandemic was low.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been declared to the CNIL (Commission nationale de l'informatique et des libertes) and the INDS (Institut National des donnees de Sante) according to the rules of the MR 004 reference method. The regulation for this type of study does not require a real authorisation but only a declaration to the institutions in accordance with the rules dictated by MR 004. University Of Corsica Pascal Paoli (IRB UCPP 2020-01) approved your study. No nominative or sensitive data on participant people have been collected. This seroprevalence study falls within the scope of the French Reference Methodology MR-004 according to 2016 41 law dated 26 January 2016 on the modernization of the French health system.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo nominative or sensitive data on participant people have been collected. This seroprevalence study falls within the scope of the French Reference Methodology MR-004 according to 2016 41 law dated 26 January 2016 on the modernization of the French health system.